Global Companion Diagnostic Market is Poised to Witness a Growth at a High Rate of ~13% from 2022 to 2027


Rising need for personalized medicine, continuous advancement in medical technology both for the diagnosis and the treatment of patients, decreased costs of genetic-based CDx tests which allow broader market access, growing cases of adverse drug reactions and side effects, and rising demand for next-generation sequencing are some of the key factors driving the global companion diagnostics market.

Companion diagnostic (CDx) is a diagnostic test used as a companion to a therapeutic drug to discover its applicability to a person. It requires multiple monitoring methods to provide extremely valuable data, allowing patients, health practitioners, and payers to decide with a higher level of certainty on the possible advantages of a treatment or care pathway.

Growing Demand for NGS-Based Technology Drives the Companion Diagnostics Market

The increasing demand for next-generation sequencing technology especially its capability to identify rare variants is crucial to continuing success and the wider distribution of companion diagnostics solutions in the market. The use of NGS panels in one test has the potential to help in the treatment of many different types of cancers. For instance,

§  In July 2022, Almac Diagnostic partnered with AstraZeneca to develop and commercialize a variety of companion diagnostic (CDx) products based on NGS and qPCR-based technologies                    


Demand for Companion Diagnostics for Targeted Cancer Drugs Drives the Companion Diagnostics Market

According to clinical research, up to 75% of cancer patients do not respond well to the same cancer treatment. In such cases, companion diagnostic tests help to indicate the presence of a molecular target and can also reveal the off-target effects of a therapeutic, predicting toxicities and adverse effects associated with a drug.

More than 90% of all globally certified CDx tests are associated with targeted cancer therapeutics. Some of the FDA-approved oncology drugs available in the market are:

Indication Type

Drug Trade Name (Generic)

Biomarker(s) Details

Approval Date

Acute Myeloid Leukemia - Peripheral Blood or Bone Marrow

Rezlidhia (olutasidenib) NDA 215814

R132 mutations (R132C, R132H, R132G, R132S, and R132L)

P170041/S006
(12/01/2022)

Non-Small Cell Lung Cancer (NSCLC) - Plasma

Krazati (adagrasib) NDA 216340

KRAS G12C

P210040
(12/12/2022)

 









Potential Role of Companion Diagnostics in Precision Medicine Drives the Companion Diagnostics Market

Personalized medicine is the practice of giving the correct dosage of the correct medicines at the correct time. Companion diagnostics, which are used to identify eligible patients for a particular therapy, are a significant driver to enable personalized treatment choices and precision medicine. Companion diagnostics offers numerous advantages in the advancement of personalized medicine and the improvement of preclinical and clinically focused drug development.

Major Challenges in Companion Diagnostics Market

The high cost of drug development therapies, associated clinical trials, the introduction of new stringent regulations for scientific validity, and analytical and clinical performance for in-vitro diagnostics (IVD) are expected to stifle growth in the companion diagnostics market in the next years.

North America is expected to hold a large share of the Companion Diagnostics Market

From a geographical standpoint, North America holds a dominant market share of the companion diagnostics market. This can be primarily attributed to the rising prevalence of diseases like cancer & HIV, improvements in regulatory guidelines, and potential economic beneļ¬ts for drug developers early in drug development in the region.

Competitive Landscape Analysis of Companion Diagnostics Market

Some of the significant players operating in the market's include Thermo Fischer Scientific Inc., Illumina Inc., Bayer AG, Danaher Corporation, Invitae, and Agilent Technologies, Inc, among others.

Organic and Inorganic Growth Strategies Deployed by Players for Gaining a Foothold in the Companion Diagnostics Market

Players operating in this market are adopting organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to gain market share. For instance,

§  In October 2022, Roche announced they have received approval from the FDA for the first companion diagnostic to identify patients with HER2-low metastatic breast cancer

§  In May 2022, Illumina, Inc. announced the incorporation of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight Oncology (TSO) Comprehensive (EU) test

 

Get Detailed Insights on Companion Diagnostics Market @ https://meditechinsights.com/companion-diagnostics-market/

Comments

Post a Comment

Popular posts from this blog

The Transplantation Market Anticipated to Expand with 9-10% CAGR by 2029 as Need for Organ Transplants Rises

Image
  The market is propelled by various factors, including advancements in medical technology, the rising prevalence of chronic diseases that lead to organ failure, increasing awareness of transplantation as a viable treatment option, and evolving regulatory and reimbursement policies. In medical terms, transplantation refers to the surgical procedure of transferring cells, tissues, or organs from a donor to a recipient to replace malfunctioning or damaged body parts. Its primary goal is to restore normal function or improve the quality of life for the recipient. Transplantation is often used to treat end-stage organ failure, severe injuries, certain cancers, and congenital defects that are not manageable through other medical treatments. This specialized field requires careful matching of donors and recipients, advanced surgical techniques, and comprehensive post-transplant care to ensure success. Types of transplantation include: Kidney Transplantation: Involves replacing a fail...
Read more

Global 3D Cell Culture Market Seeks Prosperous Horizon: Double-Digit Growth Expected by 2027

Image
  The need for organ transplants and tissue engineering combined with developments in scaffold-free technology, a rise in investments and research and development (R&D) funding for cell-based studies, growing efforts to develop potential alternatives to animal-based testing, and the rising incidence of chronic diseases are some of the major factors propelling the growth of the global 3D cell culture market. 3D cell culture   is an important approach in cell biology and tissue engineering because it includes cultivating and analyzing cells in a three-dimensional environment that mimics the circumstances present in the human body. It has several advantages, such as the capacity to recreate in vivo settings, allow the creation of complex multicellular structures, and give realistic drug testing situations. Scaffold-based technologies employing materials such as hydrogels are employed for 3D cell culturing. Its uses include cancer research, tissue engineering, and medication d...
Read more

Global Tricuspid Valve Repair Market Driven by Innovation: Set to Surge with a US$2.5 Billion Market by 2028

Image
  Increasing geriatric population, growing preference for minimally invasive procedures like annuloplasty and transcatheter tricuspid valve repair (TTVR), increased clinical research and trials activities for developing new tricuspid valve repair technologies, and rising incidence of tricuspid valve disorders are some of the key factors driving the global tricuspid valve repair market. • Medical technology advancements in the field of cardiac interventions. • Improved awareness of heart valve disorders. One of the four valves in our heart that regulates blood flow is the tricuspid valve . It is located between the ventricle and the atrium, the upper and lower chambers of our heart, on the right side. It guarantees that blood travels from the right atrium to the right ventricle in the proper path. As blood passes through the tricuspid valve, its three leaflets, or flaps, open and close. Tricuspid valve illnesses are disorders that some people have that impair the tricuspid valve's a...
Read more